Generic Engineering Construction and Projects Limited
NSE: GENCON | Information Technology
Market Fundamentals
Stock Intelligence & News
Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness
Lupin received USFDA approval for generic Pitolisant Tablets, strengthening its US portfolio and specialty generics presence. Shares remain technically weak despite strong long-term returns, with FIIs raising their stake while mutual fund holdings declined. The stock trades below most key moving averages, keeping near-term momentum subdued despite the positive regulatory development.
Read Full Analysis →Lasa Supergenerics Limited
Integrated filing for Quarter ended 30 june, 2026 |SUBJECT: Integrated Filing- Financial
Read Full Analysis →Sandoz 2Q sales beat estimates as biosimilars outpace generics; backs FY outlook
Sandoz 2Q sales beat estimates as biosimilars outpace generics; backs FY outlook
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Lasa Supergenerics Limited
Financial Results |Meeting Date: 14-Aug-2026
Read Full Analysis →Lasa Supergenerics Ltd (540702)
Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Friday, August 14, 2026, inter alia; 1. To consider, approve and take on records Unaudited financial results of the Company for the quarter ended June 30, 2026. 2. To discuss any other matter with the permission of the Chairperson.
Read Full Analysis →Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full
India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.
Read Full Analysis →Sandoz settles U.S. generic drug litigation for $450 million, reaffirms outlook
Sandoz settles U.S. generic drug litigation for $450 million, reaffirms outlook
Read Full Analysis →MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipeline
Sun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly. Strategic initiatives like semaglutide launches and the Organon acquisition are key drivers. Despite US generics pressure, domestic business and specialty products show strong momentum. Analysts maintain a positive outlook, anticipating substantial growth from these ventures.
Read Full Analysis →Trump's 200% Tariff Threat On Generic Drug Imports: What Does It Mean For India?
Trump Pharma Tariffs
Read Full Analysis →Trump's tariff policy: Abbott India, Ajanta Pharma to Alembic — pharma stocks crash up to 4%
Pharma stocks dipped on July 24 after President Trump announced a phased tariff plan for imported generic medicines, raising concerns for Indian exporters. Abbott India led losses at 3.69%, prompting fears over the future of American production and long-term impacts on stocks.
Read Full Analysis →Get instant alerts when GENCON breaks news
Join investors who track Generic Engineering Construction and Projects Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for GENCON?
GENCON is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Generic Engineering Construction and Projects Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding GENCON to your custom watchlist.